Kopran Limited , a pharmaceutical company, has reported a consolidated net loss for the second quarter of fiscal year 2026, as revenue declined year-over-year. The company's financial performance reflects challenges in the current market environment.

Financial Highlights

For the quarter ended September 30, 2025, Kopran reported the following consolidated results:

The company's revenue decreased significantly by 94.80% compared to the same quarter last year. This substantial decline in revenue contributed to a net loss of ₹992.32 lakh, compared to a profit of ₹738.41 lakh in the previous year's corresponding quarter.

Half-Year Performance

For the half-year period, Kopran's consolidated revenue stood at ₹25,312.55 lakh, compared to ₹29,099.84 lakh in the previous year, indicating a year-over-year decline.

Standalone Performance

On a standalone basis, Kopran's revenue for the quarter was ₹4,238.93 lakh, down from ₹7,352.96 lakh in the same quarter last year, representing a decrease of about 42.40%.

Board Approval and Business Operations

The Board of Directors approved these unaudited financial results at their meeting held on November 12, 2025. Kopran primarily operates in the pharmaceuticals business through its group entities.

Conclusion

Kopran's Q2 FY2026 results indicate a period of significant financial challenges for the company, with substantial declines in revenue and a shift from profit to loss. The dramatic decrease in consolidated revenue and the resulting net loss underscore the difficulties faced by the company during this quarter.

Kopran Limited , a prominent pharmaceutical company, has reported significant changes in its promoter group shareholding structure. The company disclosed these transactions in compliance with the Securities and Exchange Board of India (SEBI) regulations, highlighting the movement of shares within the promoter group.

Key Transaction Details

• Surendra Somani's Acquisition: Surendra Somani, a key member of the promoter group, acquired 35,635 shares through an off-market transaction. This acquisition increased his shareholding from 9,27,975 shares (1.92% of the total share capital) to 9,63,610 shares (2.00%).

• Kumkum Somani's Divestment: Simultaneously, Kumkum Somani sold 35,635 shares, reducing her holding from 35,635 shares (0.07% of the total share capital) to zero shares.

Impact on Shareholding Structure

The transactions have resulted in a slight redistribution of shares within the promoter group:

Unchanged Shareholdings

Several other promoter group entities maintained their existing shareholdings:

• Vandana Somani: 9,64,650 shares (2.00%)
• Varun Somani: 17,24,950 shares (3.57%)
• Oriental Enterprises Partnership Firm: 17,64,750 shares (3.65%)
• Panorama Finvest Private Ltd: 38,00,000 shares (7.87%)
• Parijat Shipping and Finale Limited: 9,11,109 shares (1.89%)
• Sarvamangal Mercantile Company Limited: 29,02,951 shares (6.01%)

Company Overview

Kopran Limited's total equity share capital remains unchanged at INR 48.28 crores.

Regulatory Compliance

These transactions were reported in accordance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosures were made to ensure transparency and compliance with regulatory requirements for listed companies.

The off-market nature of these transactions indicates that they were conducted directly between the involved parties, rather than through the open market. This approach is common for inter-se transfers within promoter groups and helps maintain stability in the company's overall ownership structure.